Workflow
长药控股(300391) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit loss of between 75 million and 50 million yuan for the fiscal year 2024, compared to a loss of 60.57 million yuan in the previous year[4]. - Total revenue is projected to be between 11 million and 15 million yuan, a significant decrease from 119.76 million yuan in the previous year[4]. - The company anticipates an asset impairment loss of approximately 673 million yuan, including goodwill impairment of about 236 million yuan and bad debt provisions of around 400 million yuan[7]. - The company’s operating income and gross margin have significantly declined due to tax payment issues and slow business operations[7]. Asset and Equity Status - The company's net assets are expected to be negative, which may lead to a delisting risk warning according to the Shenzhen Stock Exchange regulations[3]. - The expected net asset value at the end of 2024 is projected to be between -550 million and -370 million yuan, compared to 195.12 million yuan at the end of the previous year[5]. - The company’s goodwill balance as of December 31, 2023, is expected to be 236 million yuan after impairment tests[7]. Restructuring and Compliance - The company has initiated a pre-restructuring process, but there is uncertainty regarding its ability to enter formal restructuring proceedings[8]. - The company has communicated with its accounting firm regarding the performance forecast, and no significant disagreements were reported[6]. Investor Advisory - The company warns investors to be cautious and consider investment risks due to the preliminary nature of the financial data provided[9].